Arrowhead Pharmaceuticals is developing gene silencing candidates to treat obesity.[1] A phase 1/2a double-blind, escalating dose study of ARO-INHBE in obese adults is ongoing.[1][2] The study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses in part 1.[1][2] Part 2 examines the safety, tolerability, and repeated-dose pharmacodynamics in obese patients with and without type 2 diabetes receiving tirsepatide.[1][2] Part 2 will begin after the evaluation of safety data from Part 1 by day 43.[1] Obesity increases the risk of diseases such as diabetes, heart disease and stroke, while reducing fat can significantly improve patient outcomes.[1] In the US, 2 out of 5 adults are obese and it is most common between the ages of 40 and 59.[1]